Neo Ivy Capital Management Cuts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Neo Ivy Capital Management cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 60.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,956 shares of the medical research company's stock after selling 2,946 shares during the period. Neo Ivy Capital Management's holdings in Charles River Laboratories International were worth $361,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Optiver Holding B.V. acquired a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $37,000. GeoWealth Management LLC raised its stake in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after buying an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new stake in Charles River Laboratories International in the fourth quarter worth $48,000. Tortoise Investment Management LLC grew its holdings in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after purchasing an additional 115 shares during the period. Finally, Huntington National Bank grew its holdings in shares of Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company's stock valued at $55,000 after buying an additional 164 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock traded up $0.37 during trading on Thursday, reaching $136.62. The company had a trading volume of 117,783 shares, compared to its average volume of 990,104. The firm's 50-day simple moving average is $130.15 and its 200 day simple moving average is $161.88. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The firm has a market capitalization of $6.71 billion, a PE ratio of 910.45, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. During the same quarter in the previous year, the company posted $2.27 EPS. The firm's quarterly revenue was down 2.7% on a year-over-year basis. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on CRL. Evercore ISI raised shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price on the stock in a report on Thursday, May 8th. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their price target for the stock from $188.00 to $182.00 in a research note on Friday, May 23rd. JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. Finally, Mizuho reduced their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of "Hold" and an average price target of $171.85.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).